Acticor climbed 37% on the Paris Bourse on Wednesday, following the presentation of the main results of its Phase 2/3 trial in stroke, which the biotech believes opens the way to new development prospects.

As the company had already announced, the trial failed to meet its primary endpoint, which was to assess the proportion of patients still suffering severe disability or death 90 days after stroke.

The secondary endpoint, based on the proportion of patients returning to life without disability, was not met either.

But the biopharmaceutical company believes that data on certain specific subgroups are likely to open the way to new prospects.

Acticor points out that glenzocimab has indeed shown beneficial effects in certain patient populations that merit further exploration, notably in patients with complete recanalization after thrombectomy.

The company stresses that these promises will enable it to pursue its discussions with the pharmaceutical groups with whom we are in talks, with a view to refining and potentially redefining the positioning of glenzocimab in the treatment of stroke.

For the record, the company says it is in a position to finance its operations until October 2024.

Copyright (c) 2024 CercleFinance.com. All rights reserved.